|Day Low/High||108.27 / 109.26|
|52 Wk Low/High||72.13 / 122.15|
These names combine healthcare research with state-of-the art technology.
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'
The RMPIA rebounded more than 22% in the June quarter to finish up 7.8% at the 2020 half mark.
As State economies begin the slow process of reopening, the Fed is there to support market function. Facebook's latest e-commerce foray has investors cheering.
The medical device company is scheduled to report earnings this week.
The charts of the producer of medical equipment are holding up well, though its shares eventually could run into resistance.
Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.
But don't throw up your arms yet -- here are names that could be golden opportunities.
For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.
Tuesday's Dreamforce features a discussion between Salesforce's Marc Benioff and Apple's Tim Cook.
Let's see what the charts have to say.
After correction, the medical device maker could see longer-term gains to the $150-$161 area.
Top picks in the fast-growing medical products market.
Evaluating the market and policy discussion ahead of Jackson Hole, and how I am playing Zscaler on this weakness.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Let's check the charts and indicators on the glucose-monitoring company.
Amid May's market turbulence, the RMPIA was buoyed by the more than 4% rise from Medtronic.
No one knows their business as well as the CEO.
China's President Xi has obviously found surrender distasteful.
In this day and age, companies must be 'disruptors' or get left in the dust.
RMPIA soared 9.9% for the month, led by 11 double-digit gainers.
These eight S&P 500 stocks have some of the worst returns year-to-date and represent a diverse roster of promising bounce candidates.
Prices are testing the October and November lows and also testing the rising 200-day moving average line.